Use of naloxone in schizophrenic psychoses and manic syndromes.
Since 1975, different morphinomimetic peptides have been isolated from hypophyseal-hypothalamic extracts: the pentapeptides methionine-enkephalin and leucine-enkephalin, and the longer peptides alpha-, beta- and gamma-endorphin. The primary structure of most of these peptides is also present in that of beta-lipotropin. The morphinomimetic properties of endorphins can be blocked with opiate-antagonists. In rats, moreover, the endorphins influence behavior which cannot be blocked with opiate antagonists. On the basis of the hypothesis that hyperactivity of endorphin systems may be involved in the pathogenesis of schizophrenia and manic syndromes, the effect of opiate antagonists on psychotic and manic symptoms has been examined in a number of clinical studies in the past few years. A transient therapeutic effect has been demonstrated in about 30% of the patients so treated. Our own double-blind controlled study of 5 schizophrenic and 5 manic patients in the context of a World Health Organization project failed to reveal any therapeutic effect after subcutaneous injection of 20 mg naloxone. The possible reasons of the negative results are discussed.
D000341:Affective Disorders, Psychotic / Q000188:drug therapy*; D001714:Bipolar Disorder / Q000188:drug therapy*; D004311:Double-Blind Method; D004723:Endorphins / Q000378:metabolism; D006212:Hallucinations / Q000188:drug therapy; D006801:Humans; D009270:Naloxone / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*
D004723:Endorphins; D009270:Naloxone